INTRAETHNIC AND INTERETHNIC VARIABILITY IN REDUCED HALOPERIDOL TO HALOPERIDOL RATIOS

被引:27
作者
LAM, YWF
JANN, MW
CHANG, WH
YU, HS
LIN, SK
CHEN, H
DAVIS, CM
机构
[1] UNIV TEXAS,HLTH SCI CTR,DIV MATH,SAN ANTONIO,TX 78284
[2] UNIV TEXAS,COLL PHARM,AUSTIN,TX 78712
[3] MERCER UNIV,SO SCH PHARM,DEPT PHARM PRACTICE,ATLANTA,GA
[4] MERCER UNIV,SO SCH PHARM,DEPT PHARMACEUT SCI,ATLANTA,GA
[5] TAIPEI CITY PSYCHIAT CTR,TAIPEI,TAIWAN
[6] MIL 818 PSYCHIAT HOSP,TAIPEI,TAIWAN
[7] UNIV TEXAS,HLTH SCI CTR,DEPT PSYCHIAT & BEHAV SCI,HOUSTON,TX 77225
关键词
D O I
10.1002/j.1552-4604.1995.tb05000.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Steady-state haloperidol and reduced haloperidol concentrations were measured in 250 schizophrenic patients from 4 ethnic groups: 39 Blacks, 66 Caucasians, 82 Chinese, and 63 Mexican Americans. The distribution of the reduced haloperidol to haloperidol concentration (RH/HL) ratios was bimodal in all ethnic groups, with the antimode determined by probit plot os 0.46, 0.51, 0.36, and 0.76, respectively. With these antimodes, the proportion of patients with low RH/HL ratios were 41%, 42%, 73%, and 57% in the four ethnic groups, respectively. Compared with the other three ethnic groups, in the Chinese patients the ratio was lower. The mean RH/HL ratio in the Chinese was 0.34 compared with 0.81 to 0.87 in the non-Chinese groups. In 53 patients who were treated with two or more haloperidol dosage regimens, steady-state haloperidol and reduced haloperidol drug concentrations obtained from the different regimens were positively correlated with the haloperidol dose (R = .79 and R = .62, respectively). Our data suggest not only the existence of a bimodal distribution in the RH/HL ratio, but also that the antimode separating the low and high ratio subgroups is different among the various ethnic groups.
引用
收藏
页码:128 / 136
页数:9
相关论文
共 43 条
[1]  
ALTAMURA AC, 1988, PROG NEUROPSYCHOPHAR, V12, P689
[2]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397
[3]  
BOWEN WD, 1990, EUR J PHARMACOL, V17, P111
[4]   STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM [J].
BROSEN, K ;
KLYSNER, R ;
GRAM, LF ;
OTTON, SV ;
BECH, P ;
BERTILSSON, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :679-684
[5]   QUANTIFICATION OF REDUCED HALOPERIDOL AND HALOPERIDOL BY RADIOIMMUNOASSAY [J].
BROWNING, JL ;
HARRINGTON, CA ;
DAVIS, CM .
JOURNAL OF IMMUNOASSAY, 1985, 6 (1-2) :45-66
[6]  
CHAKRABORTY BS, 1989, EUR J CLIN PHARMACOL, V37, P45
[7]  
CHANG WH, 1987, BIOL PSYCHIAT, V22, P1406
[8]   PHARMACOKINETICS OF HALOPERIDOL AND REDUCED HALOPERIDOL IN CHINESE SCHIZOPHRENIC-PATIENTS AFTER INTRAVENOUS AND ORAL-ADMINISTRATION OF HALOPERIDOL [J].
CHANG, WH ;
LAM, YWF ;
JANN, MW ;
CHEN, H .
PSYCHOPHARMACOLOGY, 1992, 106 (04) :517-522
[9]   THE DETERMINATION OF ESSENTIAL CLEARANCE, VOLUME, AND RESIDENCE TIME PARAMETERS OF RECIRCULATING METABOLIC SYSTEMS - THE REVERSIBLE METABOLISM OF METHYLPREDNISOLONE AND METHYLPREDNISONE IN RABBITS [J].
EBLING, WF ;
JUSKO, WJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1986, 14 (06) :557-599
[10]   THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS [J].
EICHELBAUM, M ;
GROSS, AS .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :377-394